The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Retrovir     1-[(2R,4S,5R)-4-azido-5...

Synonyms: zidovudine, Azidothymidine, AZT Antiviral, Antiviral AZT, AZT, Antiviral, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of zidovudine


Psychiatry related information on zidovudine


High impact information on zidovudine


Chemical compound and disease context of zidovudine


Biological context of zidovudine


Anatomical context of zidovudine


Associations of zidovudine with other chemical compounds


Gene context of zidovudine

  • 10 HIV+ patients with CD4 cell counts between 200 and 500 cells/mm3 were treated with six cycles of subcutaneous recombinant IL-2 administration, in combination with zidovudine and didanosine [34].
  • MRP4 overexpression is associated with high-level resistance to the nucleoside analogues 9-(2-phosphonylmethoxyethyl) adenine and azidothymidine, both of which are used as anti-human immunodeficiency virus drugs [35].
  • METHODS: P-gp and MRP expression in response to long-term zidovudine (3'-azido-3'-deoxythymidine; AZT) or indinavir treatment was quantified by RT-PCR [36].
  • Zidovudine-based HAART recipients (n=7) also displayed significant mtDNA depletion (34.45% of control, P=0.031), increased mitochondrial protein mass (5.7-fold of control, P=0.009), and markedly increased UCP1 (18-fold of control, P=0.009) mRNA [37].
  • Reduced POT1 expression was observed in GC cell lines with telomeres shortened by treatment with azidothymidine [38].

Analytical, diagnostic and therapeutic context of zidovudine


  1. Primary infection with zidovudine-resistant HIV. Hermans, P., Sprecher, S., Clumeck, N. N. Engl. J. Med. (1993) [Pubmed]
  2. The effects on survival of early treatment of human immunodeficiency virus infection. Graham, N.M., Zeger, S.L., Park, L.P., Vermund, S.H., Detels, R., Rinaldo, C.R., Phair, J.P. N. Engl. J. Med. (1992) [Pubmed]
  3. Absence of cardiac toxicity of zidovudine in infants. Lewis, W. N. Engl. J. Med. (2001) [Pubmed]
  4. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. Fischl, M.A., Parker, C.B., Pettinelli, C., Wulfsohn, M., Hirsch, M.S., Collier, A.C., Antoniskis, D., Ho, M., Richman, D.D., Fuchs, E. N. Engl. J. Med. (1990) [Pubmed]
  5. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS. Saravolatz, L.D., Winslow, D.L., Collins, G., Hodges, J.S., Pettinelli, C., Stein, D.S., Markowitz, N., Reves, R., Loveless, M.O., Crane, L., Thompson, M., Abrams, D. N. Engl. J. Med. (1996) [Pubmed]
  6. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Foudraine, N.A., Hoetelmans, R.M., Lange, J.M., de Wolf, F., van Benthem, B.H., Maas, J.J., Keet, I.P., Portegies, P. Lancet (1998) [Pubmed]
  7. Intrathecal zidovudine for AIDS dementia. Lucht, F., Fresard, A., Brunon, J., Laurent, B., Michel, D. Lancet (1990) [Pubmed]
  8. Wernicke's encephalopathy in AIDS patient treated with zidovudine. Davtyan, D.G., Vinters, H.V. Lancet (1987) [Pubmed]
  9. Human immunodeficiency virus-associated autonomic neuropathy, drug addiction, and zidovudine treatment. Confalonieri, F., Villa, A. Arch. Intern. Med. (1993) [Pubmed]
  10. Therapeutic effects of nucleoside analogues on psychomotor slowing in HIV infection. Arendt, G., von Giesen, H.J., Hefter, H., Theisen, A. AIDS (2001) [Pubmed]
  11. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. Staszewski, S., Morales-Ramirez, J., Tashima, K.T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D.F., Farina, D., Manion, D.J., Ruiz, N.M. N. Engl. J. Med. (1999) [Pubmed]
  12. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. Gruppo Italiano per lo Studio Cardiologico dei Pazienti Affetti da AIDS. Barbaro, G., Di Lorenzo, G., Grisorio, B., Barbarini, G. N. Engl. J. Med. (1998) [Pubmed]
  13. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. Englund, J.A., Baker, C.J., Raskino, C., McKinney, R.E., Petrie, B., Fowler, M.G., Pearson, D., Gershon, A., McSherry, G.D., Abrams, E.J., Schliozberg, J., Sullivan, J.L. N. Engl. J. Med. (1997) [Pubmed]
  14. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Sperling, R.S., Shapiro, D.E., Coombs, R.W., Todd, J.A., Herman, S.A., McSherry, G.D., O'Sullivan, M.J., Van Dyke, R.B., Jimenez, E., Rouzioux, C., Flynn, P.M., Sullivan, J.L. N. Engl. J. Med. (1996) [Pubmed]
  15. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. Eron, J.J., Benoit, S.L., Jemsek, J., MacArthur, R.D., Santana, J., Quinn, J.B., Kuritzkes, D.R., Fallon, M.A., Rubin, M. N. Engl. J. Med. (1995) [Pubmed]
  16. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. Kahn, J.O., Lagakos, S.W., Richman, D.D., Cross, A., Pettinelli, C., Liou, S.H., Brown, M., Volberding, P.A., Crumpacker, C.S., Beall, G. N. Engl. J. Med. (1992) [Pubmed]
  17. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. Collier, A.C., Bozzette, S., Coombs, R.W., Causey, D.M., Schoenfeld, D.A., Spector, S.A., Pettinelli, C.B., Davies, G., Richman, D.D., Leedom, J.M. N. Engl. J. Med. (1990) [Pubmed]
  18. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. Collier, A.C., Coombs, R.W., Schoenfeld, D.A., Bassett, R.L., Timpone, J., Baruch, A., Jones, M., Facey, K., Whitacre, C., McAuliffe, V.J., Friedman, H.M., Merigan, T.C., Reichman, R.C., Hooper, C., Corey, L. N. Engl. J. Med. (1996) [Pubmed]
  19. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. Spector, S.A., Gelber, R.D., McGrath, N., Wara, D., Barzilai, A., Abrams, E., Bryson, Y.J., Dankner, W.M., Livingston, R.A., Connor, E.M. N. Engl. J. Med. (1994) [Pubmed]
  20. The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine. Aweeka, F.T., Rosenkranz, S.L., Segal, Y., Coombs, R.W., Bardeguez, A., Thevanayagam, L., Lizak, P., Aberg, J., Watts, D.H. AIDS (2006) [Pubmed]
  21. Uridine supplementation antagonizes zidovudine-induced mitochondrial myopathy and hyperlactatemia in mice. Lebrecht, D., Deveaud, C., Beauvoit, B., Bonnet, J., Kirschner, J., Walker, U.A. Arthritis Rheum. (2008) [Pubmed]
  22. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. Volberding, P.A., Lagakos, S.W., Grimes, J.M., Stein, D.S., Rooney, J., Meng, T.C., Fischl, M.A., Collier, A.C., Phair, J.P., Hirsch, M.S. N. Engl. J. Med. (1995) [Pubmed]
  23. Perinatal pharmacokinetics of zidovudine. Chavanet, P., Diquet, B., Waldner, A., Portier, H. N. Engl. J. Med. (1989) [Pubmed]
  24. Ethical challenges posed by zidovudine treatment to reduce vertical transmission of HIV. Bayer, R. N. Engl. J. Med. (1994) [Pubmed]
  25. A survey of zidovudine use in pregnant women with human immunodeficiency virus infection. Sperling, R.S., Stratton, P., O'Sullivan, M.J., Boyer, P., Watts, D.H., Lambert, J.S., Hammill, H., Livingston, E.G., Gloeb, D.J., Minkoff, H. N. Engl. J. Med. (1992) [Pubmed]
  26. Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection. Ballem, P.J., Belzberg, A., Devine, D.V., Lyster, D., Spruston, B., Chambers, H., Doubroff, P., Mikulash, K. N. Engl. J. Med. (1992) [Pubmed]
  27. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. Selwyn, P.A., Alcabes, P., Hartel, D., Buono, D., Schoenbaum, E.E., Klein, R.S., Davenny, K., Friedland, G.H. N. Engl. J. Med. (1992) [Pubmed]
  28. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. Fischl, M., Galpin, J.E., Levine, J.D., Groopman, J.E., Henry, D.H., Kennedy, P., Miles, S., Robbins, W., Starrett, B., Zalusky, R. N. Engl. J. Med. (1990) [Pubmed]
  29. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. Pizzo, P.A., Eddy, J., Falloon, J., Balis, F.M., Murphy, R.F., Moss, H., Wolters, P., Brouwers, P., Jarosinski, P., Rubin, M. N. Engl. J. Med. (1988) [Pubmed]
  30. Mitochondrial myopathy caused by long-term zidovudine therapy. Dalakas, M.C., Illa, I., Pezeshkpour, G.H., Laukaitis, J.P., Cohen, B., Griffin, J.L. N. Engl. J. Med. (1990) [Pubmed]
  31. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. Katzenstein, D.A., Hammer, S.M., Hughes, M.D., Gundacker, H., Jackson, J.B., Fiscus, S., Rasheed, S., Elbeik, T., Reichman, R., Japour, A., Merigan, T.C., Hirsch, M.S. N. Engl. J. Med. (1996) [Pubmed]
  32. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. Hardy, W.D., Feinberg, J., Finkelstein, D.M., Power, M.E., He, W., Kaczka, C., Frame, P.T., Holmes, M., Waskin, H., Fass, R.J. N. Engl. J. Med. (1992) [Pubmed]
  33. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Larder, B.A., Kemp, S.D., Harrigan, P.R. Science (1995) [Pubmed]
  34. Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects. De Paoli, P., Zanussi, S., Simonelli, C., Bortolin, M.T., D'Andrea, M., Crepaldi, C., Talamini, R., Comar, M., Giacca, M., Tirelli, U. J. Clin. Invest. (1997) [Pubmed]
  35. A family of drug transporters: the multidrug resistance-associated proteins. Borst, P., Evers, R., Kool, M., Wijnholds, J. J. Natl. Cancer Inst. (2000) [Pubmed]
  36. ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Jorajuria, S., Dereuddre-Bosquet, N., Becher, F., Martin, S., Porcheray, F., Garrigues, A., Mabondzo, A., Benech, H., Grassi, J., Orlowski, S., Dormont, D., Clayette, P. Antivir. Ther. (Lond.) (2004) [Pubmed]
  37. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Pace, C.S., Martin, A.M., Hammond, E.L., Mamotte, C.D., Nolan, D.A., Mallal, S.A. Antivir. Ther. (Lond.) (2003) [Pubmed]
  38. Expression of POT1 is associated with tumor stage and telomere length in gastric carcinoma. Kondo, T., Oue, N., Yoshida, K., Mitani, Y., Naka, K., Nakayama, H., Yasui, W. Cancer Res. (2004) [Pubmed]
  39. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Connor, E.M., Sperling, R.S., Gelber, R., Kiselev, P., Scott, G., O'Sullivan, M.J., VanDyke, R., Bey, M., Shearer, W., Jacobson, R.L. N. Engl. J. Med. (1994) [Pubmed]
  40. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. Wade, N.A., Birkhead, G.S., Warren, B.L., Charbonneau, T.T., French, P.T., Wang, L., Baum, J.B., Tesoriero, J.M., Savicki, R. N. Engl. J. Med. (1998) [Pubmed]
  41. Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine. Lipshultz, S.E., Orav, E.J., Sanders, S.P., Hale, A.R., McIntosh, K., Colan, S.D. N. Engl. J. Med. (1992) [Pubmed]
WikiGenes - Universities